Novartis scraps Fabhalta study in lupus nephritis
Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a federal clinical trials database. Fabhalta, also known as iptacopan, is a key part of Novartis' portfolio. It delivered $505 ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.